It isn’t too often that Warren Buffett is the target of criticism but after the 83 year old Billionaire spearheaded the $11 billion dollar buy out of the Canadian donut and coffee chain Tim Horton’s, there were plenty of barbs…
On Aug 28, 2014, we issued an updated research report on DIRECTV (DTV) ??? the leading U.S. satellite TV operator.
On Aug 26, 2014, we issued an updated research report on Amdocs Ltd. (DOX).
The Cooper Companies (COO) commands almost one-third market share in rapidly growing specialty lenses, multifocal lenses and torics.
On Aug 26, 2014, we issued an updated research report on Caterpillar Inc. (CAT), the mining and equipment behemoth.
Stocks suffered a disappointing week following the commencement of 10 new IPOs this week.
Leading semiconductor solutions provider Broadcom Corporation (BRCM) recently introduced a new development kit in its Wireless Internet Connectivity for Embedded Devices (WICED) family for further advancing the Internet of Things (IoT) applications.
Shares of Health Care REIT, Inc. (HCN) scaled a new 52-week high of $66.99 on Aug 27.
Sterling's (STRL) affiliate Myers & Sons Construction is a low bidder on the Las Virgenes Canyon Road project.
Cliffs Natural Resources Inc. (CLF) announced that its board of directors has authorized it to repurchase shares worth up to $200 million.
Chicago Bridge & Iron Company N.V. (CBI) recently announced that it has received a contract from the China-based Shenhua Ningxia Coal Industry Group Co. Ltd.
Primerica, Inc. (PRI) scaled a 52-week high of $50.81 on second-quarter earnings beat with year-to-date return of 18.3%, ahead of the S&P return of 8.2%.
We will share with you 5 top rated government bond mutual funds. Each has earned a Zacks #1 Rank (Strong Buy) as we expect these government bond mutual funds to outperform their peers in the future.
Financial ETFs are performing remarkably well lately.
Arrowhead Research Corporation, a biopharmaceutical company, develops targeted RNAi therapeutics in the United States. The company’s product candidate comprise ARC-520, an RNAi-based therapeutic that has completed a Phase 1 clinical trial for the treatment of chronic hepatitis B virus infection;…